Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.40 |
| ▸ | ACLY | P53396 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13739197 | 0.93 | METAP2 (0.43) | METAP2ERAP1ACLYKCNH2EPHX2 | |
| SCHEMBL13827044 | 0.86 | METAP2 (0.43) | METAP2ERAP1ACLYKCNH2EPHX2 | |
| SCHEMBL13826854 | 0.86 | METAP2 (0.43) | METAP2ERAP1ACLYKCNH2EPHX2 | |
| SCHEMBL13739143 | 0.82 | METAP2 (0.57) | METAP2 | |
| SCHEMBL13739146 | 0.82 | METAP2 (0.57) | METAP2 | |
| SCHEMBL13739783 | 0.78 | METAP2 (0.45) | METAP2ERAP1EPHX2SMN1; SMN2TP53 | |
| SCHEMBL13740196 | 0.78 | METAP2 (0.45) | METAP2ERAP1EPHX2SMN1; SMN2TP53 | |
| SCHEMBL3988647 | 0.77 | METAP2 (0.55) | METAP2 | |
| SCHEMBL13739467 | 0.76 | METAP2 (0.59) | METAP2 | |
| SCHEMBL13739472 | 0.76 | METAP2 (0.59) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561230-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9561230-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9561230-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9187494-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187494-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187494-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2705036-B1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2705036-B1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2705036-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012154678-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154678-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | DNPEP, METAP2, ANPEP | METAP2 2/4885ERAP1 47/4885ACLY 936/4885 |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, METAP2, ANPEP | METAP2 2/4885ERAP1 47/4885ACLY 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.